Indeed PSD/EFA6 shows robust activation of the Class I ARF, ARF1, when membranes are included in in vitro assays [41], and a preference for the Class I ARF GTPase ARF3, and not ARF6, in invasive prostate cancer cell lysates [42]. The gene discussed is CDKN2A; the disease is prostate cancer.